The recent review of some of the major projects in this industry sector demonstrates the positive impact of strategic ...

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is ...

In October, lenacapavir manufacturer, Gilead, announced a deal that allows six manufacturers to produce generic versions of ...

The stock's fall snapped an eight-day winning streak.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

The shot was 100% effective in preventing HIV infections in a study of women, and results published Wednesday show it worked ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis Tuesday said they have entered into an option and license agreement to discover and ...